98 Amid the 154 patents wth gA dsease at baselne, medaTTwas sgnfcantly longer the lenaldomde plus dexamethasone grouthathe dexamethasone only group.101 patents wthout gA dsease, medaTTwas agasgnfcantly longer the lenaldomde plus dexamethasone groucompared wth dexamethasone alone.Patents wth a baselne ECOG score of 0 or one alsohad a sgnfcantly longer medaTTolenaldomde plus dexamethasone thadexamethasone alone.102 Dexamethasone dose reductowas smarly assocated wth a longer TTP.the pooled subgrouanalyss of patents wth renal mparment, medaTTwas sgnfcantly longer for lenaldomde plus dexamethasone in contrast wth dexamethasone alone patents wth standard renal functon, and md, reasonable, and serious renal mpar ment104.
another subgrouanalyss of patents who receved lenaldomde plus dexamethasone, dose reductoof dexamethasone was assocated wth sgnfcantly longer TTthacontnung dexamethasone accordng to the planned dosng routine.105 Sngle agent lenaldomde Amongst 222 patents enrolled the multcenter, opelabel phase MM 014 examine, 69% of patentshad dsease professional gressoby more bonuses the end on the review wth a medaTTof five.4 months.112 RAD a phase examine of 41 patents treated for sx 28 day cycles wth lenaldomde 25 mg day odays 1 21, doxorubc9 mg m2 odays one four, dexamethasone 40 mg day odays one 4 and 17 twenty, and G CSF 6 mg oday 6, medaTTafter a medafollow uof fve months was 9.three weeks.117 General survval Lenaldomde plus dexamethasone Relatve to dexamethasone alone, medaOS was sgnf cantly prolonged patents assgned to lenaldomde plus dexamethasone each the MM 009 and MM 010 studes.two,three At a medafollow upost randomzatoof 17.
1 months the MM 009 examine, the medaOS patents assgned to lenaldomde plus dexamethasone was 29.6 months versus twenty.two months for dexamethasone alone.3 Sm larly, ATP-competitive HER2 inhibitor at a medafollow uof sixteen.5 months the MM 010 research, the medaOS patents assgned to lenaldomde plus dexamethasonehad not beereached, whereas patents assgned to dexamethasone only medaOS was estmated at twenty.six months.two Wth aextended follow uof 31.three months, the medaOS for all 704 patents pooled from each studes was 35.0 months for those recevng lenaldomde plus dexamethasone and 31.0 months for those odexamethasone alone.97 t really should be mentioned that ths sgnfcant dfference OS was mantaned despte 47% of patents recevng dexamethasone alone crossng over to lenaldomde plus dexamethasone therapy.
97 Response was correlated wth survval simply because between patents assgned to lenaldomde plus dexamethasone the medaOS was sgnfcantlyhgher for anyone who acheved CR or nCR, thafor patents who acheved

a PR.98 each MM 009 and MM 010, OS was sgnfcantly mproved the lenaldomde plus dexamethasone groucompared wth the dexamethasone only group, amid patents whohad prevously beetreated wth thaldomde.2,three addton, lenaldomde plus dexamethasone was assocated wth sgnfcantly longer OS in contrast wth dexamethasone alone, rrespectve of the variety of pror therapes.